Métricas em artrite reumatoide: uma revisão para a prática clínica

A implementação, os avanços e as atualizações das métricas de avaliação de pacientes com artrite reumatoide (AR) foram fundamentais para a dramática evolução no tratamento da doença ocorrida nas últimas décadas. Ferramentas fundamentais para a adequada padronização de desfechos para os ensaios clínicos, as métricas na AR permitem ainda uma avaliação prognóstica de fácil aplicação no consultório. Em anos recentes, as siglas DAS28, CDAI, SDAI, HAQ, RAPID-3 e PAS-II tornaram-se parte do cotidiano do reumatologista e seu adequado uso e interpretação são mandatórios para a boa prática clínica e para o acompanhamento crítico da literatura especializada. Unitermos: artrite reumatoide; avaliação de resultados em cuidados de saúde; avaliação de resultados da assistência ao paciente.

[1]  P. Louzada-Junior,et al.  Performance of the Rheumatoid Arthritis Disease Activity Index in the Assessment of Disease Activity in Rheumatoid Arthritis—Findings From the REAL Study , 2022, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[2]  Max Victor Carioca de Freitas,et al.  Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis , 2021, Advances in Rheumatology.

[3]  Lara A. Kahale,et al.  Using Parallel Streams of Evidence to Inform Guideline Development: The Case of the 2021 American College of Rheumatology Management of Rheumatoid Arthritis Guideline , 2021, ACR open rheumatology.

[4]  H. Bliddal,et al.  Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial , 2019, JAMA.

[5]  K. Michaud,et al.  Correlation of the Multi‐Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta‐Analysis , 2019, Arthritis care & research.

[6]  Matthias Schneider,et al.  Silent progression in patients with rheumatoid arthritis: is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort , 2017, BMC Musculoskeletal Disorders.

[7]  M. Dougados,et al.  Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[8]  Inge Christoffer Olsen,et al.  Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial , 2016, British Medical Journal.

[9]  D. M. van der Heijde,et al.  Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial , 2016, Annals of the rheumatic diseases.

[10]  Yoshiya Tanaka,et al.  Assessment of disease activity in rheumatoid arthritis by multi-biomarker disease activity (MBDA) score. , 2016, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.

[11]  P. Emery,et al.  Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial , 2013, Annals of the rheumatic diseases.

[12]  J. Carulli,et al.  Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis , 2013, PloS one.

[13]  H. H. Kuper,et al.  A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry , 2011, Annals of the rheumatic diseases.

[14]  M. Weinblatt,et al.  Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort , 2011, Annals of the rheumatic diseases.

[15]  M. Tomšič,et al.  Clinical contrasts with the American College of Rheumatology/European League Against Rheumatism provisional definitions of remission in rheumatoid arthritis for clinical trials: Comment on the article by Felson et al. , 2011, Arthritis and rheumatism.

[16]  W. Taylor,et al.  The Patient Activity Scale-II Is a Generic Indicator of Active Disease in Patients with Rheumatic Disorders , 2010, The Journal of Rheumatology.

[17]  T. Pincus,et al.  RAPID3 (Routine Assessment of Patient Index Data 3), a Rheumatoid Arthritis Index Without Formal Joint Counts for Routine Care: Proposed Severity Categories Compared to Disease Activity Score and Clinical Disease Activity Index Categories , 2008, The Journal of Rheumatology.

[18]  J. Smolen,et al.  The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. , 2007, Best practice & research. Clinical rheumatology.

[19]  Désirée van der Heijde,et al.  A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. , 2007, Arthritis and rheumatism.

[20]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[21]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[22]  M. A. van 't Hof,et al.  Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. , 1990, Annals of the rheumatic diseases.

[23]  D. Heijde,et al.  EFFECTS OF HYDROXYCHLOROQUINE AND SULPHASALAZINE ON PROGRESSION OF JOINT DAMAGE IN RHEUMATOID ARTHRITIS , 1989, The Lancet.

[24]  J. Moreland,et al.  Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. , 1971, Arthritis and rheumatism.